Skip to main content
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. — Investor Relations & Filings

Ticker · NAUT ISIN · US63909J1088 US Professional, scientific and technical activities
Filings indexed 299 across all filing types
Latest filing 2021-12-10 Director's Dealing
Country US United States of America
Listing US NAUT

About Nautilus Biotechnology, Inc.

https://www.nautilus.bio/

Nautilus Biotechnology, Inc. is a life sciences company developing a platform to revolutionize proteome analysis. The company's Proteome Analysis Platform is designed to quantify proteins at the single-molecule level, leveraging a proprietary method called Iterative Mapping. This technology aims to provide high-resolution views of billions of individual protein molecules and their modifications (proteoforms). The platform is being developed with two key modalities: broadscale proteomic analysis for comprehensive proteome exploration and targeted proteoform analysis for in-depth examination of protein variants. The intended applications include accelerating drug target identification, discovering more effective biomarkers, and enabling foundational biological research by making advanced proteomics more accessible to the scientific community.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-12-10 English
FORM 4
Director's Dealing
2021-12-02 English
FORM 4
Director's Dealing
2021-12-01 English
FORM 4
Director's Dealing
2021-11-24 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2021-11-17 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Quarterly Report on Form 10-Q filed with the SEC for the quarterly period ended September 30, 2021. It includes detailed financial statements such as balance sheets, statements of operations, cash flows, notes to financial statements, management's discussion and analysis, risk factors, and other comprehensive financial information. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of unaudited condensed consolidated financial statements and management's discussion confirms it is a comprehensive interim financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2021-11-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.